Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 13/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4795162 | 0.89 | HSD17B3 (0.55) | HSD17B3SCN9ANOTUM | |
| SCHEMBL4795091 | 0.86 | HSD17B3 (0.63) | HSD17B3SCN9ANOTUM | |
| SCHEMBL4800907 | 0.86 | HSD17B3 (0.63) | HSD17B3SCN9ANOTUM | |
| SCHEMBL4796700 | 0.84 | HSD17B3 (0.57) | HSD17B3NOTUM | |
| SCHEMBL4799987 | 0.82 | HSD17B3 (0.62) | HSD17B3NOTUM | |
| SCHEMBL6388516 | 0.82 | HSD17B3 (0.46) | HSD17B3SCN9ABCL2L1 | |
| SCHEMBL6388510 | 0.82 | HSD17B3 (0.46) | HSD17B3SCN9ABCL2L1 | |
| SCHEMBL6392589 | 0.77 | HSD17B3 (0.73) | HSD17B3NOTUM | |
| SCHEMBL4802970 | 0.77 | HSD17B3 (0.48) | HSD17B3 | |
| SCHEMBL4800055 | 0.76 | HSD17B3 (1.00) | HSD17B3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | HSD17B3 1/4885SCN9A 4142/4885BCL2L1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.